

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



百信集团
PASHUN GROUP

Pa Shun Pharmaceutical International Holdings Limited

百信藥業國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 574)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 8 JUNE 2017
AND
RETIREMENT OF NON-EXECUTIVE DIRECTOR**

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that all the resolutions as set out in the AGM Notice were duly passed at the AGM held on 8 June 2017.

RETIREMENT OF NON-EXECUTIVE DIRECTOR

The Board also announces that, with effect from the conclusion of the AGM, Mr. Li Ho Tan retired as a non-executive Director.

Reference is made to the circular (“**Circular**”) of Pa Shun Pharmaceutical International Holdings Limited (“**Company**”) dated 28 April 2017 in relation to the proposals for grant of general mandates to issue shares and to repurchase shares, refreshment of 10% general limit under the share option scheme, re-election of directors and change of name of the Company. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that all the resolutions as set out in the notice convening the AGM (“AGM Notice”) were duly passed by the Shareholders by way of poll at the AGM held on 8 June 2017.

As at the date of the AGM, there were a total of 1,000,000,000 Shares in issue. No Shareholder has stated in the Circular that he/she/it intended to vote against or would abstain from voting in respect of any resolutions proposed at the AGM. To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, there was no Share entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM and no Shareholder was required to abstain from voting on any of the resolutions proposed at the AGM. As such, there were a total of 1,000,000,000 Shares, representing 100% of the issued share capital of the Company as at the date of the AGM, entitling Shareholders to attend and vote for or against the resolutions proposed at the AGM.

Full text of the resolutions is set out in the AGM Notice. The poll results for those resolutions are as follows:

Ordinary resolutions		Number of Shares (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2016.	516,342,000 (100.00%)	0 (0.00%)
2.	(A) To re-elect Mr. Masahiro Honna as a Director.	516,342,000 (100.00%)	0 (0.00%)
	(B) To re-elect Mr. Zhang Xiongfeng as a Director.	516,342,000 (100.00%)	0 (0.00%)
	(C) To re-elect Mr. Liu Liangzhong as a Director.	516,342,000 (100.00%)	0 (0.00%)
3.	To authorise the Board to fix the remuneration of the Directors.	516,342,000 (100.00%)	0 (0.00%)
4.	To re-appoint CCTH CPA Limited as the auditor of the Company and authorise the Directors to fix the remuneration of the auditor of the Company.	516,342,000 (100.00%)	0 (0.00%)

Ordinary resolutions		Number of Shares (%)	
		For	Against
5.	(A) To grant the Issue Mandate to the Directors to issue, allot and otherwise deal in Shares not exceeding 20% of the number of issued Shares.	516,342,000 (100.00%)	0 (0.00%)
	(B) To grant the Repurchase Mandate to the Directors to repurchase Shares not exceeding 10% of the number of issued Shares.	516,342,000 (100.00%)	0 (0.00%)
	(C) To add, conditional upon the passing of resolutions 5(A) and 5(B), the number of the Shares repurchased by the Company under resolution 5(B) to the mandate granted to the Directors under resolution 5(A).	516,342,000 (100.00%)	0 (0.00%)
	(D) To approve the renewal of the 10% General Limit under the share option scheme of the Company.	516,342,000 (100.00%)	0 (0.00%)
Special resolution			
6.	To approve the Change of Company Name and authorise any one Director to do such acts and things and execute all documents or make such arrangements as he may in his absolute discretion consider necessary, desirable or expedient for the purpose of implementing and/or giving effect to the Change of Company Name.	516,342,000 (100.00%)	0 (0.00%)

Note: The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the AGM in person, by authorised corporate representative or by proxy.

As more than 50% of the votes were cast in favour of the ordinary resolutions proposed at the AGM, such resolutions were duly passed by the Shareholders as ordinary resolutions of the Company. As more than 75% of the votes were cast in favour of the special resolution, such resolution was duly passed by the Shareholders as a special resolution of the Company.

As the special resolution for approving the change of the English name of the Company from “Pa Shun Pharmaceutical International Holdings Limited” to “Pa Shun International Holdings Limited” and the dual foreign name in Chinese of the Company from “百信藥業國際控股有限公司” to “百信國際控股有限公司” was duly passed by the Shareholders at the AGM, the Change of Company Name will become effective from the date of entry of the new names of the Company on the register maintained by the Registrar of Companies of the Cayman Islands. Thereafter, the Company will attend to and complete any and all necessary registration and/or filing procedures with the Companies Registry in Hong Kong. The Company will make further announcement on the effective date of the Change of Company Name and the new stock short name of the Company under which Shares will be traded on the Stock Exchange in due course.

Tricor Investor Services Limited, the branch share registrar and transfer office of the Company in Hong Kong, was appointed as the scrutineer for the vote-taking at the AGM.

RETIREMENT OF NON-EXECUTIVE DIRECTOR

The Board also announces that, due to other business commitments which require more of his dedications, Mr. Li Ho Tan (“**Mr. Li**”) did not offer himself for re-election as a non-executive Director at the AGM and retired as a non-executive Director with effect from the conclusion of the AGM.

Mr. Li has confirmed that he has no disagreement with the Board and that he is not aware of any matter in connection with his retirement that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to thank Mr. Li for his contribution and services during his tenure of office.

On behalf of the Board
Pa Shun Pharmaceutical International Holdings Limited
Mr. Chen Yenfei
Chairman and Chief Executive Officer

Hong Kong, 8 June 2017

As at the date of this announcement, the executive Directors are Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian; the non-executive Directors are Mr. Zhang Xiongfeng and Mr. Masahiro Honna; and the independent non-executive Directors are Mr. Liu Liangzhong, Mr. Wong Tak Shing and Mr. Min Feng.